Junichi Ishiwata

Comparative study of methods of administering mitomycin C.

Patients with inoperable cancer were divided into three groups and treated with mitomycin C (MMC) as follows: Group 1—MMC 0.2 to 0.3 mg/kg every 14 to 20 days with glycyrrhizin iv daily. Group 2—MMC 0.12 mg/kg iv two times a week with dexamethasone 1 mg per os daily. Group 3—MMC 0.04 mg/kg iv daily. The clinical effects were evaluated in each group by the score expression of the clinical symptoms and signs on the basis of our strict criteria. The best results were obtained in group I, then in group 3 then in group 2. The results of enzymological studies in the three groups also were compared. In group 1 RNase and G6Pase activities increased for 20 days following MMC administration to the normal level. In group 2, however, the same increase lasted for only ten days. The activities in group 3 remained below the normal. A similar tendency was observed in the activities of ATPase and Beta‐GLPase.